Table 2

Factors influencing adrenocortical carcinoma (ACC) patients’ overall survival

Univariate analyses (all)Multivariate analyses (all)Multivariate analyses (localized, non-metastatic)
NHR95% PHR95% PHR95% P
Age 0.990.97 to 1.010.423
Sex
 Female75
 Male321.020.58 to 1.810.937
ENSAT stage
 I/II47
 III381.770.93 to 3.370.0811.360.58 to 3.140.4791.290.54 to 3.130.568
 IV205.282.63 to 10.57<0.0014.411.41 to 13.850.011
Resection stage
 R0/RX59
 RI/II344.942.42 to 7.98<0.0012.200.94 to 5.130.0702.670.97 to 7.360.057
Ki67 tumor index
 0%–19%52
 20%–100%412.141.17 to 3.920.0142.531.28 to 5.040.0083.131.30 to 7.520.011
Glucocorticoid excess
 –36
 +441.921.01 to 3.660.0481.370.57 to 3.280.4771.910.70 to 5.230.208
CD3
 –15
 +920.470.25 to 0.870.0160.550.23 to 1.300.1730.190.06 to 0.570.003
CD4
 –27
 +800.390.23 to 0.670.0010.580.29 to 1.180.1340.300.13 to 0.660.003
CD8
 –18
 +890.470.26 to 0.850.0130.520.23 to 1.140.1010.290.11 to 0.810.018
FoxP3
 –50
 +

570.870.52 to 1.480.6170.770.41 to 1.450.4140.640.30 to 1.360.246
Age -0.970.95 to 0.990.003
Sex
 Female38
 Male211.700.92 to 3.140.090
ENSAT stage
 I/II40
 III191.560.84 to 2.920.162
Ki67 tumor index
 0-19 %33
 20-100%234.142.09 to 8.21<0.0013.841.90 to 7.75<0.001
Glucocorticoid excess
 -26
 +221.1430.72 to 2.840.303
CD3
 -5
 +540.310.11 to 0.820.0190.420.14 to 1.290.130
CD4
 -8
 +510.430.19 to 0.940.0330.570.24 to 1.340.195
CD8
 -6
 +530.420.17 to 1.030.0490.450.17 to 1.210.113
FoxP3
 -25
 +340.750.41 to 1.380.3570.400.40 to 1.440.396
  • A, for overall survival analysis, only samples from ACC patients with primary tumors and applicable clinical data were included (n=107). For multivariate analyzes, complete available data from 83 (all) and 67 (localized, non-metastatic) ACC tumors were included out of 107 and 86 samples, respectively. Male sex, European Network for the Study of Adrenal Tumors (ENSAT) stage I/II, low proliferating Ki67 (0% to 19%), lack of glucocorticoid excess were classified as reference category.

  • B, for recurrence-free survival analysis, only samples from ACC patients with primary, localized tumors, R0/RX-state and applicable clinical data were included (n=59). For multivariate analyzes, complete available data from 56 ACC tumors (all) were included. Low proliferating Ki67 (0% to 19%) was classified as reference category in multivariate analyzes.

  • In two cases, no data regarding resection and in three cases no data about proliferation state available. Clinical data considering glucocorticoid secretion state was not determined in 11 cases.